The HER2-enriched subtype represents 10–20% of breasts cancers, with lack of ER/PR expression and overexpression of HER2; this subtype usually has high expression of Ki-67, is often more aggressive and has a worse prognosis compered to the luminal subtypes [45, 7]. This evidence concerns the gene ESR1 and breast carcinoma.